Lilly/Boehringer Ingelheim's Cymbalta now fibromyalgia market leader in USA

22 July 2012

US drug major Eli Lilly (NYSE: LLY) and German independent Boehringer Ingelheim’s Cymbalta (duloxetine) was the patient- and market-share leader in the USA in 2011 for the treatment of fibromyalgia, (duloxetine), after surpassing Pfizer’s (NYSE: PFE) Lyrica (pregabalin) in 2010, according to the latest findings of advisory firm Decision Resources.

Cymbalta garnered a 32% share of U.S. fibromyalgia patients in 2011, while Lyrica held a patient share of about 26%. According to interviewed experts, the prescribing of Cymbalta is being driven by the agent’s balance of efficacy and tolerability to patients and it has also benefited from regulatory approval for two common co-morbidities of fibromyalgia - anxiety and depression.

USA makes up 80% of major market sales for fibromyalgia therapies

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK